LXRX
Lexicon Pharmaceuticals, Inc. Healthcare - Biotechnology Investor Relations →
Lexicon Pharmaceuticals, Inc. (LXRX) closed at $2.01 as of 2026-06-19, trading 22.8% above its 200-week moving average of $1.64. The stock moved further from the line this week, up from 16.9% last week. The 14-week RSI sits at 59, indicating neutral momentum.
Trading volume is running at 1.2x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.40 ratio) is neutral — neither side is clearly dominating.
Over the past 1319 weeks of data, LXRX has crossed below its 200-week moving average 18 times. On average, these episodes lasted 60 weeks. The average one-year return after crossing below was -18.0%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $893 million, LXRX is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -16.0%. The stock trades at 4.2x book value.
Share count has increased 92.6% over three years, indicating dilution.
Over the past 25.3 years, a hypothetical investment of $100 in LXRX would have grown to $4, compared to $1011 for the S&P 500. LXRX has returned -11.6% annualized vs 9.6% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 5 open-market purchases totaling $2,722,625. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: LXRX vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After LXRX Crosses Below the Line?
Across 18 historical episodes, buying LXRX when it crossed below its 200-week moving average produced an average return of -15.6% after 12 months (median -15.0%), compared to +10.8% for the S&P 500 over the same periods. 38% of those episodes were profitable after one year. After 24 months, the average return was -30.8% vs +20.9% for the index.
Each line shows $100 invested at the moment LXRX crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Bean Score Experimental
The Bean Score measures how far a stock's free cash flow yield has deviated from its own quarterly baseline, normalized by the stock's historical behavior. LXRX currently has negative free cash flow, so price-based dislocation levels are not available. The score still tracks yield deviation from baseline.
Quarterly FCF & Yield Trailing twelve-month free cash flow and yield at each quarter end
Signal Accuracy Collecting Data
The Bean Score system is accumulating weekly data to validate signal accuracy. After 13+ weeks of history, this section will display win rates and average returns for each σ threshold crossing — answering the question: "When this score says cheap or expensive, does the price subsequently move in the expected direction?"
Theoretical framework — not backtested or forward-tested. The Bean Score uses trailing twelve-month free cash flow yield as a dislocation identifier. It measures whether the market has pushed a stock's yield unusually far from its own baseline behavior. These levels are reference points for identifying potential swing trade opportunities, not buy/sell signals. FCF values update quarterly with earnings; between reports, all movement is price-driven.
Dislocation Scores Experimental
Each score measures deviation from LXRX's own historical baseline — the same idea as the Bean Score, applied to different fundamentals. Positive means cheaper or more dislocated than this stock's norm. Scores marked σ are normalized by the stock's own variability; pp values are simple deltas from its recent baseline.
Theoretical framework — not backtested. These scores describe how unusual today's readings are for this specific company. They are starting points for research, not buy or sell signals. Annual-statement scores (buyback, accruals, FCF vs history) rest on only ~4 yearly data points and are deltas, not sigmas.
Historical Touches
LXRX has crossed below its 200-week MA 18 times with an average 1-year return of +-18.0% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Mar 2001 | Nov 2004 | 190 | 74.0% | +3.8% | -96.5% |
| Jan 2005 | Jan 2005 | 1 | 0.2% | -40.7% | -95.8% |
| Jan 2005 | Mar 2006 | 60 | 40.3% | -41.0% | -95.8% |
| Apr 2006 | Jan 2011 | 248 | 74.8% | -28.1% | -94.2% |
| Jan 2011 | Jan 2012 | 53 | 44.4% | -27.9% | -84.9% |
| May 2012 | May 2012 | 2 | 1.6% | +32.7% | -80.9% |
| Dec 2013 | Dec 2013 | 2 | 2.9% | -51.7% | -83.7% |
| Feb 2014 | Aug 2015 | 80 | 53.0% | -51.1% | -84.2% |
| Sep 2015 | Nov 2015 | 6 | 22.6% | +66.6% | -82.0% |
| Dec 2015 | Dec 2015 | 1 | 0.7% | +27.0% | -83.6% |
| Jan 2016 | Mar 2016 | 12 | 29.2% | +30.0% | -82.1% |
| May 2016 | May 2016 | 2 | 0.5% | +31.0% | -83.6% |
| Oct 2017 | May 2018 | 34 | 33.6% | -19.3% | -82.9% |
| Jul 2018 | Jan 2021 | 129 | 89.6% | -89.0% | -81.5% |
| Mar 2021 | Oct 2021 | 31 | 42.3% | -68.6% | -70.4% |
| Oct 2021 | Mar 2026 | 228 | 84.7% | -62.0% | -60.6% |
| Mar 2026 | Apr 2026 | 3 | 6.5% | N/A | +28.8% |
| Apr 2026 | May 2026 | 1 | 2.2% | N/A | +23.3% |
| Average | 60 | — | +-18.0% | — |
Frequently Asked Questions
Is LXRX below its 200-week moving average?
No. Lexicon Pharmaceuticals, Inc. (LXRX) is currently 22.8% above its 200-week moving average of $1.64. It would need to fall to $1.64 to cross below the line.
What is LXRX's 200-week moving average price?
Lexicon Pharmaceuticals, Inc.'s 200-week moving average is $1.64 as of 2026-06-19. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when LXRX drops below its 200-week moving average?
LXRX has crossed below its 200-week moving average 18 times in our data. The average one-year return after these crossings was -18.0%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 60 weeks on average.
Is LXRX a good value right now?
Here's what our data says about LXRX as of 2026-06-19: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 59. Free cash flow is currently negative. Return on equity is -16.0%. Price-to-book is 4.2x. This is not a buy or sell recommendation — always do your own research.
How does LXRX compare to the S&P 500?
Over the past 25.3 years, $100 invested in LXRX would have grown to $4, compared to $1011 for the S&P 500. That's -11.6% annualized vs 9.6% for the index. LXRX has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-06-19